Physiological Saline Market Scope And Analysis

Physiological Saline Market Report Scope

Regional Analysis

Asia Pacific is expected to register the highest CAGR in the global physiological saline market during 2022–2030. The market in Asia Pacific is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. China holds the largest share of the physiological saline market in Asia Pacific. The physiological saline market growth in China during 2020–2030 is ascribed to the rising chronic disease incidences. According to the National Health Commission of the People's Republic of China, more than 300 million patients have been diagnosed with chronic diseases, accounting for 86.6% of the total chronic disease deaths. China also reports the second-highest number of tuberculosis (TB) cases. In 2020, nearly 842,000 people were diagnosed with TB in China, as per the statistics revealed by the Centers for Disease Control and Prevention (CDC). Likewise, chronic diseases among the patients have resulted in accelerated demand for physiological saline. The UCLA Health 2023 report reveals that the medical community understood the role of dietary science and nutrition in chronic disease progression. Therefore, simple strategies such as reducing sodium intake as well as minimizing added refined sugar and saturated fat consumption can help prevent diet-associated illnesses and promote overall wellness. This nutritional content is supplied through a physiological saline solution comprising salts (sodium and potassium), sugars (carbohydrates and glucose), plant-based and animal-source diets, water intake for wellness, coffee and tea, fruit juice or soda, and so on.

The report profiles leading players operating in the physiological saline market. These include Fresenius Kabi AG, Merck KGaA, AdipoGen Life Sciences Inc, Enzo Life Sciences Inc, ICU Medical Inc, Grifols SA, Geno Technology Inc, B Braun Medical Inc, Pfizer Inc, and Ward's Science.